Edwards Lifesciences price target lowered to $80 from $90 at Barclays

Barclays analyst Matt Miksic lowered the firm’s price target on Edwards Lifesciences to $80 from $90 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the recently closed Critical Care divestiture. The analyst expects increasing interest in Edwards approaching the TCT Conference in late October, given the two key clinical catalysts scheduled for readout at the meeting, at least of one of which Barclays expects to be positive for the stock. The firm sees a path to share outperformance through year-end and 2025.